In the evolving landscape of cancer research and drug discovery, the KRAS Services Platform  has emerged as a pivotal resource for understanding oncogenic mutations and accelerating therapeutic development. KRAS mutations, which constitute approximately 95% of RAS gene alterations in human cancers, present a complex challenge due to their role in driving uncontrolled cell proliferation and tumor progression. Outsourcing KRAS assay services offers laboratories and pharmaceutical companies access to advanced technologies and expert resources without the need for extensive in-house infrastructure. This strategic approach not only enhances research capabilities but also optimizes operational efficiency, enabling faster and more reliable results. By leveraging specialized KRAS assay services, organizations can focus on core competencies while benefiting from cutting-edge assays that support precision oncology and targeted therapy development. Table of contents： How Outsourced KRAS Ser...